In the next step, the researchers want to develop new molecules based on digoxin that are even better at dissolving the CTC clusters.

Katie Elson is not yet 30. In early 2022 her partner noticed a small lump in her breast. At first they thought it was an ...

While most patients diagnosed with early breast cancer are cured eventually, approximately a third of women will eventually develop metastatic disease. Anthracyclines and taxanes are the most ...

This is not the first time lawmakers have pushed to change state laws requiring approval from insurance companies for ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...

Pfizer Inc. today announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and mFOLFOX6 (fluorouracil, ...

Natera, Inc. , a global leader in cell-free DNA and genetic testing, announced new data from the randomized, Phase III CALGB (Alliance) / SWOG 80702 study. The study will be presented today, Jan. 25, ...

Pete Hegseth Is Sworn In as Defense Secretary After Being Confirmed by Slim Margin Mr. Hegseth has vowed to bring his “warrior” ethos to the Pentagon. His confirmation came down to Vice ...

The 2-year benefit of bevacizumab in colorectal cancer may explain why survival benefits are seen in studies with two-year, ...